Humana Inc. (HUM) — Fair Value Analysis

Base-case fair value (P50): $359.23 · Current price: $305.12 · Verdict: Undervalued

The Verdict on HUM

Our Monte Carlo simulations indicate that Humana (HUM) is currently undervalued. Trading at $305.12, the stock sits below our median fair value (P50) of $359.23. This suggests a potential +17.7% upside from its current market price, according to our probabilistic valuation framework for the Healthcare sector.

How HUM stacks up against Healthcare

While our analysis points to undervaluation for HUM, it's important to consider the company's operational and financial health. Humana is categorized with a "weak" quality tier when measured against its Healthcare sector peers. This assessment reflects specific underlying fundamentals that, despite the current valuation gap to $359.23, warrant investor attention. The projected +17.7% needs to be viewed in the context of this relative quality standing.

What this means for investors

For investors, the +17.7% potential, as identified by our Monte Carlo simulations comparing $305.12 to $359.23, highlights a notable valuation opportunity in Humana. However, the "weak" quality tier suggests that while the stock appears cheap on a probabilistic basis, fundamental risks or challenges are present. FairCurve provides a deeper look into these dynamics. To fully understand the range of potential outcomes for HUM, including detailed bear and bull scenarios and to track its fair value as new fundamentals are released, sign up for a free FairCurve account.